Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant aspects of the physiology, mechanisms of action, pharmacology, and data from studies with animal models and human subjects. Cannabis has been used to treat disease since ancient times. Δ(9) -Tetrahydrocannabinol (Δ(9) -THC) is the major psychoactive ingredient and CBD is the major nonpsychoactive ingredient in cannabis. Cannabis and Δ(9) -THC are anticonvulsant in most animal models but can be proconvulsant in some healthy animals. The psychotropic effects of Δ(9) -THC limit tolerability. CBD is anticonvulsant in many acute animal models, but there are limited data in chronic models. The antiepileptic mechanisms of CBD are not known, but may include effects on the equilibrative nucleoside transporter; the orphan G-protein-coupled receptor GPR55; the transient receptor potential of vanilloid type-1 channel; the 5-HT1a receptor; and the α3 and α1 glycine receptors. CBD has neuroprotective and antiinflammatory effects, and it appears to be well tolerated in humans, but small and methodologically limited studies of CBD in human epilepsy have been inconclusive. More recent anecdotal reports of high-ratio CBD:Δ(9) -THC medical marijuana have claimed efficacy, but studies were not controlled. CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic-ischemic encephalopathy. However, we lack data from well-powered double-blind randomized, controlled studies on the efficacy of pure CBD for any disorder. Initial dose-tolerability and double-blind randomized, controlled studies focusing on target intractable epilepsy populations such as patients with Dravet and Lennox-Gastaut syndromes are being planned. Trials in other treatment-resistant epilepsies may also be warranted. A PowerPoint slide summarizing this article is available for download in the Supporting Information section here.

Real-time target selection optimization to enhance alignment of gas chromatograms.

An improved method for real-time selection of the target for the alignment of gas chromatographic data is described. Further outlined is a simple method to determine the accuracy of the alignment procedure. The target selection method proposed uses a moving window of aligned chromatograms to generate a target, herein referred to as the window target method (WTM). The WTM was initially tested using a series of 100 simulated chromatograms, and additionally evaluated using a series of 55 diesel fuel gas chromatograms obtained with four fuel samples. The WTM was evaluated via a comparison to a related method (the nearest neighbor method (NNM)). The results using the WTM with simulated chromatograms showed a significant improvement in the correlation coefficient and the accuracy of alignment when compared to the alignments performed using the NNM. A significant improvement in real-time alignment accuracy, as assessed by a correlation coefficient metric, was achieved with the WTM (starting at ∼ 1.0 and declining to only ∼ 0.985 for the 100th sample), relative to the NNM (starting at ∼ 1.0 and declining to ∼ 0.4 for the 100th sample) for the simulated chromatogram study. The results determined when using the WTM with the diesel fuels also showed an improvement in correlation coefficient and accuracy of the within-class alignments as compared to the results obtained from the NNM. In practice, the WTM could be applied to the real-time analysis of process and feedstock industrial streams to enable real-time decision making from the more precisely aligned chromatographic data.